The market situation, which is increasingly put under pressure, has caused AJ Vaccines to pause parts of its production of vaccines against tetanus, diphtheria and whooping cough (TdaP). This decisions will lead to 40 positions being shut down within the company.
AJ Vaccines CEO Jesper Helmuth Larsen says as much in an interview with MedWatch. More specifically, the production of the active ingredients in these three vaccines is halted for a period of time, whereas AJ Vaccines will try to make the production more cost-efficient.
Get full access for you and your coworkers.Start a free company trial today
Already a member? Log in.